TriSalus Life Sciences (TLSIW) Accounts Payables (2020 - 2026)

TriSalus Life Sciences (TLSIW) has 7 years of Accounts Payables data on file, last reported at $4.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 50.82% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.2 million (up 50.82% YoY), and the FY2025 full-year result was $3.0 million, up 32.01% from the prior year.
• Accounts Payables for Q1 2026 stood at $4.2 million, up from $3.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $4.9 million in Q4 2022 and bottomed at $765244.0 in Q2 2022.
• The 5-year median for Accounts Payables is $2.3 million (2024), against an average of $2.4 million.
• The widest annual swing landed in 2022, when Accounts Payables soared 367.75%; it then slumped 32.94% in 2024.
• A 5-year view of Accounts Payables shows it stood at $4.9 million in 2022, then tumbled by 31.45% to $3.4 million in 2023, then plunged by 32.94% to $2.3 million in 2024, then jumped by 32.01% to $3.0 million in 2025, then surged by 40.97% to $4.2 million in 2026.
• The last three Accounts Payables figures came in at $4.2 million (Q1 2026), $3.0 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.

Peer Comparison